The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Congratulations to all long term patient holders of Anglo American today two and a half years in the making and we’ve finally secured a joint venture deal with Junior behemoth prospect Arc Minerals taking us back to our old hunting grounds and previous licenses in Zambia over 20 years ago. Now with a fresh outlook to investment the Zambian government is officially open for business again. More tier 1 deposits on the way with David Wood at the held looking for the missing copper.
https://youtu.be/WfOQ2Qc_h1Y
So, one more week of the 4th or 5th extension lost count now. C’mon the cadastre sort it out!
Just found out that because I bought on 15/12 I didn’t qualify, I thought that was the last day to buy for Jan divi but actually was the 14/12. Well that’s annoying was hoping for the extra cash for a winter break away, Mrs won’t be happy now …ha
Does anyone that’s with HL know if they have to do anything to get their dividend payments? I set mine for Jan to be paid directly in bank account, anyone in the same situation still waiting for their divi payment to come?
Anyone know when the Feb dividend RNS gets confirmed?
Cheers
Most definitely. This share is in phase 2/3 of a US government funded trail the same master trial that approved monoclonal antibody drugs from Eli Lilly etc.
The at home Activ 2 trial is huge and I don’t think it’s really even been factored into the market. This is directly funded by operation warp speed. If there is enough efficacy for the at home trial this could thousands of pounds per patient of hospital admissions. We know from previous research as well that Interferon works best earlier in the disease progression of Covid when the virus replicates mostly in the nasopharyngeal tract (nose and throat) before migrating into the lungs and then subsequently causing blood clots etc. The best time to take SNG 001 is earlier in the disease hence this trial is perfect for SNG 001.
With the backing of the US government and it progressing from stage 2 seamlessly into phase 3 we know there haven’t been any serious adverse events in phase 2.
We know this antiviral drug is safe and the mechanism of action of inhalation straight into the lungs provides an unrivalled chance for it to produce targeted positive effects with minimal toxicities.
I personally believe there is just a good a chance if not a better chance to have a really good return on investment even more chance now then prior to the results of P2 in July 2020.
of the virus in the lower respiratory tract and, in the scenario where hospitals are at capacity, treating patients in the home setting could be the only option. We hope to gain valuable data from this trial, which will aid us in progressing approval of SNG001 as a treatment for COVID-19."
Mon, 25th Jan 2021 07:00
RNS Number : 6835M
Synairgen plc
25 January 2021
Press release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
ACTIV partnership is funded by "Operation Warp Speed", led by the US Government's Department of Health and Human Services and designed to speed up the development of the most promising treatments and vaccine candidates for COVID-19
Southampton, UK - 25 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces a clinical trial agreement to include its inhaled interferon beta-1a treatment (SNG001) in the ACTIV-2/A5401 Phase II/III trial in patients with COVID-19 not yet requiring hospitalisation. The trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
NIH's Accelerating COVID-19 Therapeutic Inventions and Vaccines (ACTIV) (https://www.nih.gov/research-training/medical-research-initiatives/activ) is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising treatments and vaccine candidates for COVID-19. ACTIV-2 is a master protocol designed for evaluating multiple investigational agents compared to placebo in adults with mild-to-moderate COVID-19, not requiring hospitalisation.
The Phase II/III ACTIV-2 study, led by the NIAID-funded AIDS Clinical Trials Group (ACTG), is an adaptive, randomised, blinded, placebo-controlled trial. The Phase II evaluation of SNG001 will see the recruitment of up to a maximum of 220 participants across US sites, in a home-based setting, split between SNG001 and placebo, and a positive result enables progression into the Phase III part of the study.
NIAID is the regulatory sponsor and holder of the Investigational New Drug application to conduct the ACTIV-2 study, which is funded by Operation Warp Speed, a partnership led by the US Department of Health and Human Services through NIAID, to investigate and coordinate the development, manufacturing, and distribution of COVID-19 diagnostics, therapeutics and vaccines.
Richard Marsden, CEO of Synairgen, said: "The inclusion of our inhaled interferon beta-1a treatment in the US Government-funded ACTIV-2 trial reflects the strong interest that our Phase II data has generated and the Company's strong belief that this drug could play a vital role in the treatment of COVID-19. As an inhaled treatment, SNG001 offers ease of use that makes it possible for patients to administer it conveniently at home, reducing the risk of virus transmission during hospital visits and relieving the major logistical strain on healthcare systems.
At-home treatments also have the potential to be taken much earlier in the course of the illness, preventing the progression o
Standard of care
Very sorry to everyone. I was in Synairgen before news came out of the phase 2 trails in July 2020 should of sliced at the top and ended up selling all at around £1. However at the moment this is an absolute bargain, and have just gone back in at 25p, with results to come of the at home trail and then COPD to consider. The dust will settle of this and it will gently start rising back towards 60-80p
Birmingham 2022: Esports to be included as pilot event at Commonwealth Games
I have a good source that the Narni Bridge is going to be linked with Binance Smart chain. This is likely to be within the next month. Then further down the line Solana and Avalanche will be worked on.
This is huge news for online blockchain and the Umbria Network
I think Mr Bird will soon be going on a weekly Zak Mir interview spree once those results start flowing in from bushranger and Africa
Open to the northwest did I hear
I am an optimist however I think the axing of Covid certification in England right now could be a good thing for CTEA as the plan was to only include double jabbed as qualifying. However this now gives time for this approach to be scrutinised to include other reasons to qualify such as having had Covid and having antibodies which can be proved with antibody tests and also taking a test recently to prove not infectious which I’d argue if more safe at reducing spread than just being double jabbed as we know you can still pass it on and have Covid after being double jabbed.
If anyone needs to average down now is the time considering what happened at phase 1 last time. Let’s get near to that 2M tonnes of copper or alternatively force Anglo American’s hand with an offer off the back of the open pit and “decision to mine”
Does anyone know how long it might take to get an updated Jorc once all of the phase 2 results are in?
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-set-rule-controversial-biogen-alzheimers-drug-2021-06-07/
If I’m not mistaken Foralumab will also be used for Alzheimer’s disease in the future. Biogen are gonna make billions per year from this one
I think this 3rd wave hype is a ploy to once again usher in new laws that give the government more powers within the coronavirus act 2020. Such changes in law will undoubtedly be the use of COVID passports to verify vaccination or current test status.
Good times for Catenae ahead in the next few months no doubt. This will treble on hype without even any contracts.
Yes I do. They have an 80% buyback clause for Bushranger racecourse deposit, that is currently being explored by Xtract Resources. Looks like it could be a winner like Arcm!